KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EBITDA (2016 - 2025)

Historic EBITDA for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $853.1 million.

  • Regeneron Pharmaceuticals' EBITDA rose 41.2% to $853.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.6 billion, marking a year-over-year increase of 233.41%. This contributed to the annual value of $4.6 billion for FY2025, which is 233.41% up from last year.
  • According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' EBITDA is $853.1 million, which was up 41.2% from $1.5 billion recorded in Q3 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' EBITDA registered a high of $3.1 billion during Q2 2021, and its lowest value of $725.7 million during Q1 2024.
  • Over the past 5 years, Regeneron Pharmaceuticals' median EBITDA value was $1.2 billion (recorded in 2021), while the average stood at $1.3 billion.
  • Its EBITDA has fluctuated over the past 5 years, first soared by 22895.21% in 2021, then tumbled by 7423.19% in 2022.
  • Regeneron Pharmaceuticals' EBITDA (Quarter) stood at $2.2 billion in 2021, then crashed by 43.77% to $1.2 billion in 2022, then rose by 1.79% to $1.3 billion in 2023, then tumbled by 32.33% to $849.6 million in 2024, then increased by 0.41% to $853.1 million in 2025.
  • Its last three reported values are $853.1 million in Q4 2025, $1.5 billion for Q3 2025, and $1.4 billion during Q2 2025.